Equities researchers at StockNews.com began coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Get Free Report) in a research report issued to clients and investors on Sunday. The firm set a “sell” rating on the stock.
Navidea Biopharmaceuticals Price Performance
Shares of NYSE:NAVB opened at $0.00 on Friday. The company has a market cap of $100,084.00, a P/E ratio of -0.02 and a beta of 1.46. Navidea Biopharmaceuticals has a 12 month low of $0.00 and a 12 month high of $0.13.
About Navidea Biopharmaceuticals
Featured Stories
- Five stocks we like better than Navidea Biopharmaceuticals
- 3 Warren Buffett Stocks to Buy Now
- 3 Small-Cap Stocks on the Way to Bigger and Better Days
- Using the MarketBeat Stock Split Calculator
- MarketBeat Week in Review – 9/30 – 10/4
- What is the Hang Seng index?
- Top Streaming Companies: Who’s Winning the Battle?
Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.